Treatment with trastuzumab induced a slight growth reduction in SKBR-3 cells cultured in 2D, whereas proliferation was strongly inhibited in the 3D spheroids mirroring the clinical benefit of trastuzumab for ErbB2-positive breast cancer patients [47]. The gene discussed is ERBB2; the disease is breast carcinoma.